AI toothbrushes, free-from formulas and sweet flavors reshape oral care
The once stagnant oral care industry is experiencing surging interest with tooth tech in the spotlight. The industry is also tapping “free-from” claims and flavors appealing to Gen Z as brands move into the thus-far under-utilized sparse market.
UK Agri-Tech Centre to slash workforce by 60% in strategic pivot to new operating model
The UK Agri-Tech Centre (UKATC) has completed a consultation that will reduce its workforce by 60% from 130 to 50 staff …
AgriFood Signals: India’s Scimplify nets $25m, Deere funds food security, USDA funds seed research
AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…
Drought-Resistant Seeds: Are They Reaching the Farmers Who Need Them?
15 For years, scientists have worked to develop seeds that can withstand drought and give farmers a better chance of har…
GLP-1 users and Gen Z steer collagen to skin longevity
Collagen and its anti-aging properties are now expected to work more precisely and under the messaging of longevity. The industry movement is pushed by consumers demanding scientific proof and the rising use of GLP-1 medications.
OSE reports positive Phase 2 data, but questions remain
Why it matters: Tedopi has already shown signs of activity in patients with advanced non-small cell lung cancer (NSCLC) who have exhausted standard treatments, but its clinical benefit remains uncertain. The latest results reinforce the vaccine’s potential without clearly demonstrating that combining it with chemotherapy or another immunotherapy provides additional efficacy.
Nigerian Agritech Startups Can Compete for ₦30m in SMEDAN Pitch Competition
12 Nigerian agritech startups and agribusinesses can compete for ₦30 million in grants through SMEDAN’s Zero to 100 pitc…
US beauty consumers prioritize ingredient transparency over brand image
US consumers increasingly prefer dermatologically and scientifically backed formulations over brand-based authority, according to an OnSkin survey.
CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch
🇬🇧 AstraZeneca pulls prostate cancer filing: UK pharma AstraZeneca withdrew its application to expand Truqap (capivasertib) into PTEN-deficient metastatic hormone-sensitive prostate cancer. Truqap blocks AKT, a protein involved in cancer-cell growth, and is already used in certain breast cancers. The proposed prostate cancer use was particularly notable because the FDA approved it in June after a Phase 3 trial showed that adding Truqap to hormone therapy reduced the risk of disease progression or death by 19%. EMA has confirmed the withdrawal, but a detailed explanation has not yet been published.
PETA warns BEMT use will cost US beauty brands’ cruelty-free status
PETA (People for the Ethical Treatment of Animals) will remove cosmetics companies from its Ultimate Cruelty-Free List if they use bemotrizinol (BEMT).
